Brepocitinib
pfizer
['derm']
aggarwal et al. tyk2/jak1i brepoctinib in dermatomyositis. supportive clinical and pharmacological evidence, plus efficacy of other jak agents, likely to lead to a clinical trial. #acr22 abstr#0157 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC